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ABSTRACT Neurocysticercosis accounts for approximately 30% of all epilepsy cases
in most developing countries. The immunodiagnosis of cysticercosis is complex and
strongly influenced by the course of infection, the disease burden, the cyst location,
and the immune response of the host. The main approach to immunodiagnosis
should thus be to evaluate whether the serological results are consistent with the
diagnosis suggested by imaging. Antibody detection is performed using lentil lectin-
purified parasite antigens in an enzyme-linked immunoelectrotransfer blot format,
while antigen detection uses a monoclonal antibody-based enzyme-linked immu-
nosorbent assay (ELISA). Promising new assay configurations have been devel-
oped for the detection of both antibody and antigen, including assays based on
synthetic or recombinant antigens that may reduce costs and improve assay repro-
ducibility and multiplex bead-based assays that may provide simultaneous quantita-
tive results for several target antigens or antibodies.
KEYWORDS Peru, Taenia solium, Western blot, antibody, antigen, cysticercosis,
neurocysticercosis, EITB, ELISA
Taenia solium, the pork tapeworm, is endemic in most developing countries wherepigs are raised. The coexistence of domestic pig raising and poor sanitary condi-
tions enables the establishment of the parasite life cycle, in which pigs get infected with
the larval cystic stage (cysticercus) by ingesting infective Taenia eggs excreted in the
stools of a human carrying the adult intestinal tapeworm. Humans, in turn, get infected
with the adult tapeworm stage by ingesting cysts in poorly cooked pork. Humans may
also host the larval stage and acquire cysticercosis by fecal-oral contamination (1).
While cysts in most tissues are asymptomatic and rarely noticed, cysts in the nervous
system (neurocysticercosis [NCC]) are a major cause of epilepsy and other neurological
morbidities in regions of endemicity (2, 3). Cases of NCC are seen in regions where it is
not endemic with increasing frequency because of travel and migration. In the United
States, more than 1,800 NCC-related hospitalizations are estimated to occur per year.
The hospitalization costs for cysticercosis exceed those for malaria and all other
neglected tropical diseases combined (4).
CYSTICERCOSIS INFECTION
Very little is known regarding the usual evolution of human cysticercosis infections.
In the pig model, the embryos contained in ingested tapeworm eggs are released, cross
the intestinal mucosa, migrate through the circulatory system, and develop into
cysticerci that reach their definitive size in 3 to 4 months. Cysticerci are typically found
in muscle and subcutaneous tissue and less frequently in the nervous system (5). There
is no reason to suspect that this initial process is different in humans than in pigs.
Neurocysticercosis: parasite stages, localization, and clinical manifestations. It
is generally accepted that although human cysticercosis affects multiple tissues, the
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parasite is usually destroyed by the host’s immune system, surviving mainly in immu-
nologically privileged sites like the brain or the eye. The infection of the nervous system
is more likely to result in prominent symptoms and therefore more likely to be
diagnosed than infections of other tissues. Despite this, it is likely that most infections
remain undiagnosed for months or years. The evidence from a large series of NCC cases
occurring in British soldiers who served in India for a defined period demonstrated
that in a significant proportion of cases, neurological symptoms present years after
infection (6).
The process by which embryos invade the central nervous system has not been
clearly elucidated. However, once infection is established, the evolution of cysticerci in
the human nervous system follows a somewhat predictable course. Viable intraparen-
chymal brain cysts develop into rounded vesicles composed of a thin parasitic mem-
brane filled with a clear cerebrospinal fluid (CSF)-like fluid and containing a retracted
tapeworm head (scolex). There is evidence that the parasite employs multiple active
immune evasion mechanisms to avoid recognition (7). Pericystic inflammation at this
initial stage is minimal or nonexistent. At some point, the host’s immune system detects
the parasite and launches a cellular response with local perilesional inflammation that
gradually leads to the death of the cyst. The fluid inside the cyst becomes turbid and
dense, the cyst shrinks, and remnant parasite tissue is eventually cleared or replaced
with a residual calcification (Fig. 1).
In contrast, cysts that develop in the subarachnoid spaces may not result in rounded
vesicles. Without the constraints of surrounding brain parenchyma, the cyst membrane
may infiltrate and grow into neighboring spaces and cavities, resulting in large cystic
structures or cyst clumps invading wide areas of the subarachnoid space (Fig. 2). This
is frequently accompanied by a profuse inflammatory reaction characterized by CSF
pleocytosis, an elevated protein concentration, and low glucose. Cysts in the ventricles
are usually individual vesicles that frequently do not cause symptoms, although in
some cases, cysts may block CSF circulation leading to hydrocephalus.
The location of the parasites in the human nervous system determines the clinical
manifestations of the infection. Parenchymal brain cysts primarily manifest with sei-
zures and epilepsy, though headache, focal signs, and cognitive deficits are not
uncommon. Ventricular and subarachnoid cysts present as space-occupying lesions
with or without hydrocephalus and with headache and intracranial hypertension as the
most frequently associated symptoms.
Evolution of the immunological diagnosis in NCC. The initial attempts at immu-
nodiagnosis date back to complement fixation described by Weinberg in 1909 and later
adapted by Nieto in Mexico in the early 1940s (8). Hemagglutination and radioimmu-
noassay were used for many years despite suboptimal sensitivity and specificity (9).
Soon after the advent of the enzyme-linked immunosorbent assay (ELISA), several
teams applied this technique to cysticercosis with good results (10–13), though cross-
reactions with other helminth infections (including Echinococcus, Hymenolepis, and
FIG 1 Macroscopic views of cysticerci in different stages of involution.
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Schistosoma, among others) were frequent. In 1989, the introduction of the enzyme-
linked immunoelectrotransfer blot using lentil lectin-bound glycoproteins (LLGP-EITB)
significantly improved the performance of immunodiagnosis.
All of the above-described assays are based on the detection of antibodies, taking
advantage of the multiplier effect of the antibody production system in the host. The
detection of antigen was deemed poorly efficient (14, 15) until the use of monoclonal
antibodies (MAbs) enabled improved ELISAs. Two assays for veterinary use detecting
Taenia saginata cysticercosis in cattle were developed in Europe using MAbs against T.
saginata, one using the HP10 MAb from Edinburgh (16) and the other using the
B158-B60 antibodies from Antwerp (17). These MAbs are cross-reactive with T. solium in
pigs and Taenia ovis in sheep but not with other common cestodes that infect humans,
such as Hymenolepis nana or Echinococcus granulosus. These assays were initially
reported to be useful to support the diagnosis of NCC using CSF (15) and were
subsequently demonstrated to have similar utility for serum (18–21) and urine (22, 23).
ANTIBODY DIAGNOSIS
Assays. The reference assay for antibody detection is the LLGP-EITB (9). This assay
uses a lentil lectin-purified glycoprotein antigen mixture that is separated by gel
electrophoresis, transferred to nitrocellulose paper, and then cut into strips. A strip is
placed in a well containing the sample (usually serum or CSF) and incubated overnight.
Conjugated goat anti-human IgG antibody is then added to reveal antigen-antibody
reactions that appear as dark bands on the strip. Reactions to one or more of the seven
LLGP antigens are considered positive.
In clinical settings, the diagnostic performance of the LLGP-EITB performed in serum
samples is very high, approaching 98% sensitivity and 100% specificity in patients with
more than one viable brain cysticercosis cyst (9). In patients with a single viable or
degenerating cyst, the sensitivity is lower (60% to 70%) (24). The presence of circulating
antibodies detectable by LLGP-EITB in patients with only calcified lesions is extremely
variable and likely affected by the burden of the original infection and the time since
resolution. Currently, the LLGP-EITB assay is available through the CDC Parasitic Disease
Reference Laboratory for clinical diagnosis in U.S. cases.
FIG 2 Basal subarachnoid neurocysticercosis (magnetic resonance imaging).
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Antibody detection ELISAs have mostly used semipurified somatic parasite or cyst
fluid antigens. Their performance in general is poor, with suboptimal sensitivity and
frequent cross-reactions with other common cestode infections such as hymenolepiasis
or hydatid disease (25). Some authors suggest that antibody detection in an ELISA is
more specific and substantially more sensitive when performed in CSF rather than in
sera. In research settings, good test accuracies have been obtained in several platforms
of ELISAs (traditional ELISA, FAST-ELISA, and QuickELISA) using recombinant or syn-
thetic antigens (26–28), though these assays have not yet become commercially
available.
Antigens. A systematic list of antigens used for antibody diagnosis in cysticercosis
can be found in the article by Rodriguez et al. (24). In short, the first antigen charac-
terized was the dominant antigen B, which was described in Mexico in 1980. As the use
of antigen B did not demonstrate much advantage over other antigen sources, and
further characterizations of antigenic proteins were carried out. After the LLGP antigens
were characterized and applied in the EITB format, this assay became the reference
assay for serodiagnosis. Other assays based on the LLGP antigens have been developed
(9, 26–31). The LLGPs belong to three families, including the GP50, T24, and 8-kDa
families.
The GP50 protein is a glycosylated and glycosylphosphatidylinositol (GPI)-anchored
membrane protein. The native protein migrates at 50 kDa, but the predicted molecular
weight of the mature protein is 28.9. Expressed in a baculovirus expression system,
recombinant GP50 in an EITB assay showed 100% specificity for cysticercosis and 90%
sensitivity for cysticercosis-positive serum samples reactive with the GP50 component
of LLGP (30).
The T24 protein is an integral membrane protein that belongs to the tetraspanin
superfamily. It migrates at a position corresponding to 24 kDa and as a homodimer at
42 kDa. A portion of T24, the large extracellular loop domain, was expressed in an
immunologically reactive form in insect cells and also in bacterial cells. When tested in
a EITB assay with several well-defined batteries of serum samples (ranging from 149 to
249 NCC cases, as well as from 131 to 401 negative controls), this protein, T24H, has a
sensitivity of 94% for detecting cases of cysticercosis with two or more viable cysts and
a specificity of 98% (27, 29, 31).
The 8-kDa proteins are the diagnostic proteins found at 14, 18, and 21 kDa lentil
lectin-bound fraction from urea-solubilized cysticerci and are also found in the bands
at 24 and 39 to 42 kDa of LLGP. The 8-kDa family is likely composed of extracellular
secreted proteins that accumulate in the cyst fluid. This family consists of 4 clades of
proteins (TsRS1, TsRS2, Ts14, and Ts18), and from each representative clade, a synthetic
peptide has been produced and evaluated as a diagnostic antigen.
Samples. Serum samples are preferred for antibody diagnosis. CSF has the advan-
tage of being in more direct contact with the CNS infection, but its collection requires
a lumbar puncture, an invasive and moderately painful procedure that is poorly
accepted in some cultures. In general, antibody detection by EITB is similarly sensitive
in serum as in CSF, and antibody detection by ELISA seems higher in CSF (32). However,
CSF examination may complement the serological diagnosis and also add information
such as cell counts and CSF biochemistry. Antibodies can be also found in saliva
samples (32).
Antibody profiles by type of NCC. The presence of specific antibodies does not
definitively indicate active cysticercosis infection, since antibodies can result from
exposure to the parasite and from infections that did not establish or were resolved at
very early stages. In fact, a positive LLGP-EITB result can be found in up to 20% to 25%
of some rural populations where the parasite is endemic and all of these scenarios are
present (33). Moreover, in settings of endemicity, transient antibody responses have
been reported to be relatively common in both humans and pigs, suggesting that
exposure is frequent and does not necessarily result in sustained seropositivity (34).
However, the strength of the antibody response, and the particular profile of individual
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LLGP reactions, can provide useful information in the clinical setting. Positive antibody
responses in asymptomatic people from populations where the parasite is endemic are
usually characterized by weak reactions against GP50 only or to GP50 and GP42-39. In
contrast, antibody reactions in clinical cases are much stronger and frequently involve
all the LLGP families. We have been able to dilute a serum sample from a patient with
subarachnoid NCC 16 times before the EITB became negative (Fig. 3). A recent study
described the associations between LLGP-EITB antibody banding patterns and brain
imaging findings in 548 NCC cases. Samples with a negative result or with only
antibodies to GP50 were associated with nonviable or single viable parenchymal
cysticerci, and samples with low-molecular-weight antibodies (8-kDa family) were more
likely to be from extraparenchymal NCC or multiple viable intraparenchymal cysts (35).
Longevity of antibody responses in NCC. One of the drawbacks of antibody
detection is that the life span of the antibody response is extremely variable and likely
dependent on the immune history of the host, the burden of infection, and other
variables. Thus, some individuals with infections involving multiple cysts may have
persistently detectable antibodies on LLGP-EITB years after successful antiparasitic
treatment, while others may become seronegative after 9 months or so (36). While
seroreversion to negative is a marker of cure, waning of the antibody response over less
than a year is not the norm in most patients. Antibodies to the 8-kDa antigens are the
first to disappear, followed by antibodies to GP24 and GP42-39. Antibodies to GP50 are
the most persistent. Patients presenting with only calcified NCC lesions may still have
persistently positive reactions; the positive EITB result in these cases does not neces-
sarily imply the presence of undetected viable parasitic cysts, particularly in cases with
weak or decreasing antibody responses. On the other hand, strong LLGP-EITB reactions
(4 to 7 bands) in a patient with calcified NCC may indicate the presence of viable cysts,
though the predictive value is lower than that of antigen detection (35).
ANTIGEN DETECTION
A diagnosis by antigen detection is limited by the amount of circulating antigens
that are produced or released from the parasites, unlike the antibody responses that
have been amplified by the host’s immune system.
Assays. The introduction of MAb-based antigen detection ELISAs improved the
specificity of the tests and enabled their use for the diagnosis of human NCC. These
FIG 3 Sustained EITB response despite sequential (2-fold) dilutions of a strong positive serum sample.
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assays use a sandwich ELISA technique with one MAb as the capture antibody and a
different MAb as the detection antibody.
Antibodies. Two assays have been described in the literature. One of them uses
HP10 and HP6 antigens, and another assay from a different group utilizes MAbs B158
and B60. All of these MAbs were developed against Taenia saginata but cross-react with
Taenia solium, enabling the diagnosis of viable cysticercosis. The HP10 and HP6
monoclonal antibody pairs were developed by injecting antigens from viable cysts into
mice and were screened against lentil lectin-adherent glycoproteins from T. saginata
cysts (16, 17). The HP10 monoclonal antibody is an IgM class antibody and recognizes
an epitope present on a heterogeneous group of phosphorylcholine-bearing, lentil
lectin-adherent trichloroacetic acid-soluble glycoproteins present on the surface and in
the secretions of the T. saginata cysticerci (16).
The B158 and B60 monoclonal antibodies were developed against the excretory
secretory antigens of T. saginata-viable cysticerci. These monoclonal antibodies are of
an IgM antibody class and recognize bands at 87 kDa and 100 kDa of somatic extracts
of adult T. saginata and also at 65 kDa from excretory-secretory antigens of T. saginata
cysticerci (17). The performances of these assays appear to be comparable. One
commercial version of the B158 assay (cysticercosis AG ELISA; ApDia, Turnhout, Bel-
gium) is available in the United States.
Samples. Antigen detection was initially reported using CSF but later also reported
to be possible using serum and urine. While there are no published controlled data,
antigen levels appear to be higher in CSF than in serum. As mentioned above for
antibody detection, serum is the preferred sample.
The same advantages (sample being in more direct contact with the CNS infection)
and disadvantages (more invasive and less acceptable) apply regarding CSF versus the
other samples types.
Antigen profiles by type of NCC. Detectable levels of circulating antigen demon-
strate the presence of live parasite cysts in the host. Patients with only calcified NCC
should therefore be antigen negative, and a positive result in this scenario should make
the clinician suspect that viable lesions have been missed by imaging. The results of
antigen testing are frequently negative in patients with a degenerating cyst or with one
or a few viable parenchymal cysts and consistently positive in patients with several
viable parenchymal cysts. The levels of circulating antigens are very high in patients
with subarachnoid NCC, to the extent of frequently saturating the assay detection limit.
Longevity of antigen responses in NCC. Unlike circulating antibodies, antigen
levels drop fairly quickly after a successful course of antiparasitic therapy in which all
viable parasites are destroyed. The resolution of extensive subarachnoid NCC may,
however, take several courses of antiparasitic treatment.
Role of immunological diagnosis in the diagnosis of NCC. Understanding how
immunological assays can best contribute to the diagnosis of NCC is not as intuitive as
it may sound. To begin with, brain imaging is a key part of the evaluation of a patient
suspected to have NCC and should be used to establish the diagnosis, define the key
characteristics of the infection, and determine the medical or surgical treatment
approaches. The diagnosis suggested by imaging needs to be considered when
evaluating serological results. For example, it is important to consider that the levels of
antigens and antibodies vary enormously depending on the stage and number of the
parasites present. In general, it is to be expected that most patients with viable
infections would be seropositive for both antibodies and antigens. However, patients
with a single lesion may test negative for either, and patients with a low infection
burden may be antigen negative but positive for antibodies. Patients with only calcified
lesions are typically antigen negative, and many of them will also be antibody negative,
though a proportion of them will continue having detectable levels of circulating
antibodies due to the persistence of the response months or years after the parasites
have died. Subarachnoid NCC is commonly associated with very high levels of circu-
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lating antigens and antibodies; thus, a negative or weak result should raise questions
about the diagnosis.
Role of immunological diagnosis to screen for cysticercosis or NCC infections.
A frequent question is whether immunodiagnostic assays should be used to identify
people suspected of having NCC in areas of endemicity where confirmatory brain
imaging is not possible. We contend that the utility of this approach is limited, as
immunodiagnosis using the tests that are currently available would not modify the
clinical management for the vast majority of people with either asymptomatic or
symptomatic NCC. In addition, most experts will not prescribe antiparasitic treatment
in the absence of brain imaging, because the risks associated with the resulting
inflammatory response depend greatly on the number and location of viable cysts
present.
At the population level, most individuals with asymptomatic NCC will have only
calcified disease. While it is not known what proportion of these will develop epilepsy
or other neurological symptoms, clinical management is limited to the administration
of antiepileptic drugs or other symptomatic measures regardless of serologic status. A
smaller proportion of individuals with NCC will have viable or degenerating cysts.
Again, an unknown but likely small proportion will go on to develop symptoms, and
the prognosis with or without antiparasitic treatment is favorable. However, an even
smaller proportion will have a large CNS cyst burden (many cysts) or early subarachnoid
NCC involvement, with substantial risk of disease progression or complications. In our
assessment, the only potential contribution of an immunological screening test for NCC
would be to identify this small subset, as early intervention could potentially improve
the prognosis and reduce long-term costs. These potential benefits have yet to be
demonstrated. Clinical management of these patients also requires brain imaging.
The scenario is similar for individuals with symptomatic NCC. The majority will have
epilepsy secondary to parenchymal brain cysticercosis and should be managed with
antiepileptic drugs regardless of serologic status. There is no indication for antiparasitic
treatment in the sizable proportion of clinical cases presenting with calcified NCC only.
Although symptomatic individuals with few viable cysts may benefit from antiparasitic
drugs, the clinical prognosis with symptomatic management is again favorable, and the
blind use of antiparasitic treatment in cases with cysts in delicate locations such as the
brainstem or individuals with large cyst burdens may be deleterious or even lethal.
Those with severe neurologic manifestations such as intracranial hypertension require
referral for brain imaging, and neurosurgery will be indicated independent of whether
the symptoms are due to NCC. As mentioned above, the utility of screening may be
limited to identifying those individuals with a heavy cyst burden or subarachnoid
involvement.
Future trends in immunological diagnosis. The limited availability of the LLGP-
EITB is a serious drawback. The preparation of the antigens used on the test strips
requires a complex purification process that is both expensive and difficult to stan-
dardize, as well as dependent on the availability of parasite material. Because of this
complex and labor-intensive process, the adaptation to a version involving titers does
not seem a practical alternative. In recent years, however, representative proteins for all
three antigenic protein families have been developed in either recombinant (rGP50 and
rT24) or synthetic (sTSRS1, sTS18var1, sTSRS2var1, and sTs14) forms that may reduce
costs and improve assay reproducibility. Standardized EITB assays using these new
antigens are now available in the research setting (26–31) but require validation in a
variety of settings of endemicity to better understand their performance and limita-
tions. These efforts are under way.
Another drawback is that the result is qualitative and requires considerable expe-
rience for the correct interpretation of the banding profile. A quantitative, multiplex
bead-based assay, such as the Luminex platform, offers the possibility of simultaneously
detecting cysticercosis antigens as well as quantifying the antibody response to each
specific cysticercosis antigen. A quantitative assay would provide an estimate of the
intensity of the antibody response (improving diagnostic accuracy) and would also
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enable a direct comparison of antibody levels between samples (providing a guide for
monitoring therapy or following the evolution of the infection). This platform assay also
enables the possibility of combining testing for cysticercosis with other diseases, which
could be beneficial for integrated control programs. With respect to antigen detection,
new MAbs that are specific to Taenia solium and that have greater binding capacity to
improve detection sensitivity are needed.
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